Last reviewed · How we verify

CT327 0.05% — Competitive Intelligence Brief

CT327 0.05% (CT327 0.05%) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: 11β-HSD1 inhibitor. Area: Rheumatology.

phase 2 11β-HSD1 inhibitor 11β-HSD1 Rheumatology Small molecule Live · refreshed every 30 min

Target snapshot

CT327 0.05% (CT327 0.05%) — Creabilis SA. CT327 is a selective inhibitor of 11β-HSD1.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
CT327 0.05% TARGET CT327 0.05% Creabilis SA phase 2 11β-HSD1 inhibitor 11β-HSD1
lorundrostat Dose 1 lorundrostat Dose 1 Mineralys Therapeutics Inc. phase 3 11β-HSD1 inhibitor 11β-HSD1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (11β-HSD1 inhibitor class)

  1. Creabilis SA · 2 drugs in this class
  2. Mineralys Therapeutics Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CT327 0.05% — Competitive Intelligence Brief. https://druglandscape.com/ci/ct327-0-05. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: